Atlas Trials

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

Clinical trial NCT06175390 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06175390
Sponsor
Institut Curie
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2024-03-27
Primary completion
2026-08-15
Enrollment
81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.